166 Notes to the financial statements 43 Principal Group companies The following represent the principal subsidiary and associated undertakings of the GlaxoSmithKline Group at 31st December 2009.
Details are given of the principal country of operation, the location of the headquarters, the business sector and the business activities.
The equity share capital of these undertakings is wholly owned by the Group except where its percentage interest is shown otherwise.
All companies are incorporated in their principal country of operation except where stated.
Location Subsidiary Sector Activity % Europe England Brentford GlaxoSmithKline Holdings Limited Ph, CH h Brentford GlaxoSmithKline Holdings One Limited Ph, CH h Brentford GlaxoSmithKline Services Unlimited Ph, CH s Brentford GlaxoSmithKline Mercury Limited Ph h Brentford GlaxoSmithKline Finance plc Ph, CH f Brentford GlaxoSmithKline Capital plc Ph, CH f Brentford SmithKline Beecham Limited Ph, CH d e h m p r Brentford Wellcome Limited Ph, CH h Brentford Glaxo Group Limited Ph h Brentford Glaxo Operations UK Limited Ph p Brentford GlaxoSmithKline Export Limited Ph e Brentford GlaxoSmithKline Research & Development Limited Ph d r Brentford GlaxoSmithKline UK Limited Ph m p Brentford Setfirst Limited Ph, CH h Brentford The Wellcome Foundation Limited Ph p Cambridge Domantis Limited Ph d r Brentford SmithKline Beecham Overseas Limited Ph h Brentford SmithKline Beecham Holdings UK Limited Ph h Brentford ViiV Healthcare Limited Ph h 85 Brentford ViiV Healthcare UK Limited Ph m s 85 Brentford ViiV Healthcare Trading Services Limited Ph e f 85 Austria Vienna GlaxoSmithKline Pharma GmbH Ph m Belgium Genval GlaxoSmithKline S. A. Ph m Rixensart GlaxoSmithKline Biologicals S. A. Ph d e m p r Czech Republic Prague GlaxoSmithKline s. r. o. Ph, CH m Denmark Orestadt GlaxoSmithKline Consumer Healthcare A S CH m Brndby GlaxoSmithKline Pharma A S Ph m Finland Espoo GlaxoSmithKline Oy Ph m France Marly le Roi Groupe GlaxoSmithKline S. A. S. Ph h Marly le Roi Laboratoire GlaxoSmithKline S. A. S. Ph m r d Marly le Roi Glaxo Wellcome Production S. A. S. Ph p Marly le Roi GlaxoSmithKline Sante Grand Public S. A. S. CH m St. Amand Les Eaux GlaxoSmithKline Biologicals S. A.
S Ph p Germany Buehl GlaxoSmithKline Consumer Healthcare GmbH & Co. KG CH d h m p r s Munich GlaxoSmithKline GmbH & Co. KG Ph d h m p r s Greece Athens GlaxoSmithKline A. E. B. E Ph, CH m Hungary Budapest GlaxoSmithKline Medicine and Healthcare Products Limited Ph, CH e m Italy Verona GlaxoSmithKline S. p. A. Ph d h m r Milan GlaxoSmithKline Consumer Healthcare S. p. A. CH m Verona GlaxoSmithKline Manufacturing S. p. A. Ph p GSK Annual Report 2009 Financial statements P91P182 Business review P06P53 Governance and remuneration P54P90 Financial statements P91P182 Shareholder information P183P204 167 Notes to the financial statements 43 Principal Group companies continued Location Subsidiary Sector Activity % Europe Luxembourg Mamer GlaxoSmithKline International Luxembourg S. A. R. L Ph, CH f h Netherlands Zeist GlaxoSmithKline B. V. Ph m Utrecht GlaxoSmithKline Consumer Healthcare B. V. CH m Norway Oslo GlaxoSmithKline AS Ph m Poland Poznan GlaxoSmithKline Pharmaceuticals S. A. Ph p 97 Poznan GSK Services Sp.
z o. o. Ph m Warsaw GlaxoSmithKline Consumer Healthcare Sp.
z o. o. CH m e Portugal Alges  Farmaceuticos, Limitada Ph m Republic of Carrigaline SmithKline Beecham Cork Limited i Ph d p r Ireland Cork GlaxoSmithKline Trading Services Limited i Ph e Dublin GlaxoSmithKline Consumer Healthcare Ireland Limited i CH m Dublin GlaxoSmithKline Ireland Limited Ph m Dungarvan Stafford Miller Ireland Limited i CH p Dungarvan GlaxoSmithKline Dungarvan Limited i CH p Romania Brasovi Europharm Holding S. A. Ph, CH s Bucharest GlaxoSmithKline GSK S. R. L. Ph m r s Russian Moscow GlaxoSmithKline Trading ZAO Ph m Federation Moscow GlaxoSmithKline Healthcare ZAO CH m Spain Madrid GlaxoSmithKline S. A. Ph m Madrid GlaxoSmithKline Consumer Healthcare S. A. CH m Aranda fide Duero Glaxo Wellcome, S. A. Ph p Sweden Solna GlaxoSmithKline AB Ph m Switzerland Muenchenbuchsee GlaxoSmithKline AG Ph m USA USA Coral Gables Stiefel Laboratories, Inc. Ph h m p Hamilton Corixa Corporation Ph m p Philadelphia GlaxoSmithKline LLC Ph, CH d e h m p r s Pittsburgh GlaxoSmithKline Consumer Healthcare, L. P. CH m p 88 Pittsburgh Block Drug Company, Inc. CH h m Wilmington GlaxoSmithKline Holdings Americas Inc. Ph, CH h Wilmington GlaxoSmithKline Capital Inc. Ph f Cambridge Sirtris Pharmaceuticals Inc. Ph r Research Triangle Park ViiV Healthcare Company Ph m 85 Americas Bermuda Hamilton GlaxoSmithKline Insurance Ltd Ph, CH i Canada Mississauga GlaxoSmithKline Inc. Ph m p r Oakville GlaxoSmithKline Consumer Healthcare Inc. CH m Laval ID Biomedical Corporation Ph h Quebec City ID Biomedical Corporation of Quebec Ph d m p r Mexico Delegacion Tlalpan GlaxoSmithKline Mexico S. A. fide C. V. Ph, CH e m p s Ph m Puerto Rico Guaynabo GlaxoSmithKline Puerto Rico Inc. Asia Pacific Australia Boronia GlaxoSmithKline Australia Pty Ltd Ph, CH d e m p r China Beijing GlaxoSmithKline China Investment Co. Ltd Ph, CH d h m Hong Kong GlaxoSmithKline Limited Ph, CH m Shanghai GlaxoSmithKline Biologicals Shanghai Ltd Ph m p Tianjin Sino-American Tianjin Smith Kline & French Laboratories Ltd CH d m p r 55 GSK Annual Report 2009 168 Notes to the financial statements 43 Principal Group companies continued Location Subsidiary Sector Activity % Asia Pacific India Mumbai GlaxoSmithKline Pharmaceuticals Limited Ph m p 51 Nabha GlaxoSmithKline Consumer Healthcare Limited ii CH m p 43 Malaysia Petaling Jaya GlaxoSmithKline Pharmaceutical Sdn Bhd Ph m Selangor GlaxoSmithKline Consumer Healthcare Sdn Bhd CH m New Zealand Auckland GlaxoSmithKline NZ Limited Ph, CH m Pakistan Karachi GlaxoSmithKline Pakistan Limited Ph, CH m p e 79 Philippines Makati GlaxoSmithKline Philippines Inc Ph, CH m Singapore Singapore Glaxochem Pte Ltd Ph h Singapore Glaxo Wellcome Manufacturing Pte Ltd Ph d h p r Singapore GlaxoSmithKline Pte Ltd Ph, CH m South Korea Seoul GlaxoSmithKline Korea Limited Ph, CH m Thailand Bangkok GlaxoSmithKline Thailand Limited Ph, CH m Japan Japan Tokyo GlaxoSmithKline K. K. Ph, CH d m p Latin America Argentina Buenos Aires GlaxoSmithKline Argentina S. A. Ph, CH d e m p r Brazil Rio fide Janeiro GlaxoSmithKline Brasil Limitada Ph, CH e m p Colombia Bogota GlaxoSmithKline Colombia S. A. Ph, CH m Venezuela Caracas GlaxoSmithKline Venezuela, C. A. Ph, CH m Middle East & Africa Egypt Cairo GlaxoSmithKline S. A. E Ph m p 91 South Africa Bryanston GlaxoSmithKline South Africa Pty Limited Ph, CH m p Turkey Istanbul GlaxoSmithKline Ilaclari Sanayi five Ticaret A. S. Ph, CH m Location Associate Sector Activity % USA USA Madison Quest Diagnostics Incorporated iii Clinical testing 17 Middle East & Africa South Africa Johannesburg Aspen Pharmacare Holdings Limited iii Ph, CH m p r 19 i Exempt from the provisions of Section 7 of the Companies Amendment Act 1986 Ireland.
ii Consolidated as a subsidiary undertaking in accordance with Section 1162 4 a of the Companies Act 2006 on the grounds of dominant influence.
iii Equity accounted on the grounds of significant influence.
Directly held wholly owned subsidiary of GlaxoSmithKline plc.
Key Business sector: Ph Pharmaceuticals, CH Consumer Healthcare Business activity: d development, e exporting, f finance, h holding company, i insurance, m marketing, p production, r research, s service Full details of all Group subsidiary and associated undertakings will be attached to the companys Annual Return to be filed with the Registrar of Companies.
Each of GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc is a wholly-owned finance subsidiary of the company, and the company has fully and unconditionally guaranteed the securities issued by each of GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc.
GSK Annual Report 2009 Financial statements P91P182
